Eliaz Therapeutics

Eliaz Therapeutics is developing a novel treatment method using targeted therapeutic apheresis. Our mission is to alter the course of life-threatening diseases to improve survival rates and prevent long-term illness and disability. Eliaz Therapeutics is developing a novel medical device to selectively remove galectin-3 from the blood. Galectin-3 (Gal-3) is a key mediator and known critical driver of organ inflammation and fibrosis in many acute and chronic progressive diseases. In critically ill patients, the development of AKI and sepsis is associated with elevated plasma Gal-3 levels. When Gal-3 is blocked in animal models, the rate of AKI significantly decreases and survival rates increase.